Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population

  • Borrego-Hernández, Daniel
  • Vázquez-Costa, Juan Francisco
  • Domínguez-Rubio, Raúl
  • Expósito-Blázquez, Laura
  • Aller, Elena
  • Padró-Miquel, Ariadna
  • García-Casanova, Pilar
  • Colomina, María J.
  • Martín-Arriscado, Cristina
  • Osta, Rosario
  • Cordero-Vázquez, Pilar
  • Esteban-Pérez, Jesús
  • Povedano-Panadés, Mónica
  • García-Redondo, Alberto
Intermediate CAG expansions in the gene ataxin-2 (ATXN2) are a known risk factor for ALS, but little is known about their role in FTD risk. Moreover, their contribution to the risk and phenotype of patients might vary in populations with different genetic backgrounds. The aim of this study was to assess the relationship of intermediate CAG expansions in ATXN2 with the risk and phenotype of ALS and FTD in the Spanish population. Repeat-primed PCR was performed in 620 ALS and 137 FTD patients in three referral centers in Spain to determine the exact number of CAG repeats. In our cohort, ≥27 CAG repeats in ATXN2 were associated with a higher risk of developing ALS (odds ratio [OR] = 2.666 [1.471–4.882]; p = 0.0013) but not FTD (odds ratio [OR] = 1.446 [0.558–3.574]; p = 0.44). Moreover, ALS patients with ≥27 CAG repeats in ATXN2 showed a shorter survival rate compared to those with <27 repeats (hazard ratio [HR] 1.74 [1.18, 2.56], p = 0.005), more frequent limb onset (odds ratio [OR] = 2.34 [1.093–4.936]; p = 0.028) and a family history of ALS (odds ratio [OR] = 2.538 [1.375–4.634]; p = 0.002). Intermediate CAG expansions of ≥27 repeats in ATXN2 are associated with ALS risk but not with FTD in the Spanish population. ALS patients carrying an intermediate expansion in ATXN2 show more frequent limb onset but a worse prognosis than those without expansions. In patients carrying C9orf72 expansions, the intermediate ATXN2 expansion might increase the penetrance and modify the phenotype.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Differentially expressed lncRNAs in SOD1G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic later

  • López-Royo, Tresa
  • Moreno-Martínez, Laura
  • Zaragoza, Pilar
  • García-Redondo, Alberto
  • Manzano, Raquel
  • Osta, Rosario
Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease characterized by progressive motor function and muscle mass loss. Despite extensive research in the field, the underlying causes of ALS remain incompletely understood, contributing to the absence of specific diagnostic and prognostic biomarkers and effective therapies. This study investigates the expression of long-non-coding RNAs (lncRNAs) in skeletal muscle as a potential source of biomarkers and therapeutic targets for the disease. The expression profiles of 12 lncRNAs, selected from the literature, were evaluated across different disease stages in tissue and muscle biopsies from the SOD1G93A transgenic mouse model of ALS. Nine out of the 12 lncRNAs were differentially expressed, with Pvt1, H19 and Neat1 showing notable increases in the symptomatic stages of the disease, and suggesting their potential as candidate biomarkers to support diagnosis and key players in muscle pathophysiology in ALS. Furthermore, the progression of Myhas and H19 RNA levels across disease stages correlated with longevity in the SOD1G93A animal model, effectively discriminating between long- and short-term survival individuals, thereby highlighting their potential as prognostic indicators. These findings underscore the involvement of lncRNAs, especially H19 and Myhas, in ALS pathophysiology, offering novel insights for diagnostic, prognostic and therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

LncRNA levels in the central nervous system as novel potential players and biomarkers in amyotrophic lateral sclerosis

  • López-Royo, Tresa
  • Moreno-Martínez, Laura
  • Rada, Gabriel
  • Macías-Redondo, Sofía
  • Calvo, Ana Cristina
  • García-Redondo, Alberto
  • Manzano, Raquel
  • Osta, Rosario
Research in amyotrophic lateral sclerosis (ALS) faces major burdens, including the urgent need for sensitive and specific biomarkers, the identification of novel and effective therapeutic targets and a deeper understanding of the mechanisms driving the disease. In this line, long non-coding RNAs (lncRNAs) have emerged as promising candidates due to their regulatory role in a variety of important biological processes such as RNA metabolism, neuroinflammation, apoptosis or proteostasis. This study aims to elucidate the expression profile of 14 lncRNAs in both the SOD1G93A mouse model and ALS patients. Different stages of the disease (presymptomatic, symptomatic and terminal) and 3 regions of the central nervous system (CNS) differentially affected by ALS (spinal cord, brainstem and frontal cortex) were included in the experimental design. In SOD1G93A mice, all 14 lncRNAs exhibited differential expression patterns influenced by sex, age, and region, except for Malat1, Neat1, and H19, which displayed consistent expression patterns (Malat1 was decreased, while Neat1 and H19 were increased). These patterns were most prominent in the spinal cord, where lncRNAs were overall down-regulated. In contrast, in the brainstem and frontal cortex, lncRNAs were predominantly up-regulated. Notably, Gas5 expression levels in frontal cortex and spinal cord at the terminal stage correlated with the onset and progression of motor coordination and strength decline. Additionally, three lncRNAs (Gas5, Neat1 and Myoparr) were found to significantly correlate with survival. In human ALS samples, increased levels of NEAT1 and SNHG16 were observed in the brainstem, and of MEG3 and H19 in the frontal cortex, whereas MALAT1 levels were decreased in frontal cortex. In conclusion, this work supports lncRNAs as promising candidates as novel players and potential biomarkers in ALS and highlights SOD1G93A mice as a good model to study lncRNAs in the CNS in the context of this disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Clinical parameters predicted the progression to dementia in oldest old patients with mild cognitive impairment (MCI)

  • Molina-Torres, Nora
  • Platero, Carlos
  • Pérez-Berasategui, Oscar
  • Andrés-Benito, Pol
  • Povedano, Mónica
  • Mesa-Lampré, Pilar
  • Abadía-Morales, María
  • Calvo, Ana-Cristina
  • Lobo, Antonio
  • De La Cámara-Izquierdo, Concepción
  • Osta, Rosario
Background: This study intends to assess to what extent instruments commonly used in clinical practice, as well as plasma p-tau-181, can predict the progression from MCI to dementia. The usefulness of a disease progression model (DPM) is also explored. Methods: A longitudinal, prospective nested case-control study was conducted with patients from the Geriatrics outpatient clinics who met the MCI International Working Group criteria. The patients had a first clinical interview and two follow-ups after 12 and 24 months. Validated Spanish instruments were used for assessment, including the Mini-Mental State Examination (MMSE), the clock test, verbal fluency, the EURO-D depression scale, Barthel’s Index, and Lawton’s Index. P-tau-181 analysis was performed with SIMOA (Single MOlecule Array). A robust parametric disease progression model (RPDPM) was developed. Results. Fifty-nine patients fulfilled the inclusion criteria. The median age was 82.7 + /−8.7 years, 93 % had amnestic MCI and 45.8 % progressed to dementia (ICD-11 criteria) in two years. P-tau-181 was not prognostic. An RPDPM with the MMSE, clock test, and Lawton’s Index could predict progression to dementia with an AUC of 0.945. Conclusion: A combination of the MMSE, clock test, and Lawton’s Index in a DPM model predicted progression from MCI to dementia best. P-tau and other blood biomarkers did not predict progression. Our results highlight the strength of clinical variables to predict the progression of MCI.